Eli Lilly and Company

Vincent Mancuso

Michael J Martinelli

Christopher William Doecke

Chaoyu Xie

Matthew Joseph Fisher

Karin Briner

Paul Leslie Ornstein

Steven Lee Kuklish

Jeffrey Thomas Mullaney

Ryan Thomas Backer

Qing Shi

Timothy Ivo Richardson

Zhipei Wu

Freddy Andre Napora

John M Schaus

Yao-Chang Xu

Joseph H Krushinski, Jr

Larry W Hertel

Daniel Timothy Kohlman

Frantz Victor

Bai-Ping Ying

Sidney Xi Liang

Michael Philip Cohen

Deyi Zhang

Roger Ryan Rothhaar

Ana Isabel Mateo Herranz

John Philip Mayer

Cristina Garcia-Paredes

Uko Effiong Udodong

DeAnna Piatt Zacherl

Jikesh Arvind Shah

Daniel Edward Verral, Ii

Ivan Collado Caño

Oscar De Frutos Garcia

Caño Ivan Collado

Oscar De Frutos-Garcia

Christopher Kelly Biggers

The invention relates to compounds of formula I:   The compounds of the present invention are useful for activating 5-HTreceptors, inhibiting neuronal protein extravasation, and for the treatment or prevention of migraine in a mammal. The present invention also relates to a process for the synthesis of intermediates in the synthesis of compounds of Formula I.

[object Object]

The present invention relates to compounds of formula I: or pharmaceutically acceptable acid addition salts thereof, where; Ris C-Calkyl, substituted C-Calkyl, C-Ccycloalkyl, substituted C-Ccycloalkyl, C-Ccycloalkyl-C-Calkyl, substituted C-Ccycloalkyl-C-Calkyl, phenyl, substituted phenyl, heterocycle, or substituted heterocycle; Ris hydrogen, C-Calkyl, C-Ccycloalkyl-C-Calkyl, or a group of formula II  Ris hydrogen or C-Calkyl; Ris hydrogen, halo, or C-Calkyl; Ris hydrogen or C-Calkyl; Ris hydrogen or C-Calkyl; and n is an integer from 1 to 6 inclusively. The compounds of the present invention are useful for activating 5-HTreceptors, inhibiting neuronal protein extravasation, and for the treatment or prevention of migraine in a mammal. The present invention also relates to a process for the synthesis of intermediates in the synthesis of compounds of Formula I.

The present invention relates to melanocortin receptor agonist of the formula (I): which is useful in the treatment for obesity, diabetes, and male and/or female sexual dysfunction 

Melanocortin receptor agonists

The present invention relates to melanocortin receptor agonists of formula (I), which is useful in the treatment of obesity, diabetes and male and/or female sexual dysfunction 

The present invention relates to melanocortin receptor agonists of formula I, which is useful in the treatment of obesity, diabetes and male and/or female sexual dysfunction 

Piperazine- and piperidine-derivatives as melanocortin receptor agonists

The present invention relates to melanocortin receptor agonist of the formula I useful in the treatment of obesity, diabetes, and male and/or female sexual dysfunction 

Substituted piperidines/piperazines as melanocortin receptor agonists

5-HT1f agonist

The present invention provides processes and intermediates of Formula I: ##STR1## where X and R are defined in the specification, for the preparation of 5-amino-3-(1-methylpiperidin-4-yl)pyrrolo-[3,2-b]pyridine.

Pyrrolo [3,2-b]pyridine processes and intermediates

Growing community of inventors

Thy-Le-Chateau, Belgium

Vincent Mancuso